Coral Budesonide Coral Budesonide

X

Find Radio Compass News for Budesonide

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

JP

0

Other Listed Suppliers

SERVICES
left grey arrow
right gray arrow
  • SPRAY, METERED;NASAL - 0.032MG/SPRAY
  • SUSPENSION;INHALATION - 0.25MG/2ML
  • SUSPENSION;INHALATION - 0.5MG/2ML
  • SUSPENSION;INHALATION - 1MG/2ML
  • CAPSULE, DELAYED RELEASE;ORAL - 6MG
  • CAPSULE, DELAYED RELEASE;ORAL - 9MG
  • CAPSULE, DELAYED RELEASE;ORAL - 3MG
  • AEROSOL, METERED;INHALATION - 0.08MG/INH;0.0045MG/INH
  • AEROSOL, METERED;INHALATION - 0.16MG/INH;0.0045MG/INH

https://endpts.com/takeda-wins-long-awaited-us-approval-for-first-oral-drug-for-eosinophilic-esophagitis/

ENDPTS
13 Feb 2024

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-7-2024-67267.pdf

FDA
07 Feb 2024

https://www.businesswire.com/news/home/20240122150188/en

BUSINESSWIRE
22 Jan 2024

https://www.prnewswire.com/news-releases/everest-medicines-announces-new-drug-application-acceptance-of-nefecon-in-taiwan-for-the-treatment-of-primary-iga-nephropathy-in-adult-patients-302022659.html

PR NEWSWIRE
26 Dec 2023

https://www.fiercepharma.com/pharma/calliditas-wins-over-fda-full-approval-broader-label-tarpeyo

FIERCE PHARMA
21 Dec 2023

https://www.prnewswire.com/news-releases/everest-medicines-partner-calliditas-therapeutics-announces-nefecon-the-only-fda-approved-treatment-for-iga-nephropathy-to-significantly-slow-kidney-function-decline-302020586.html

PR NEWSWIRE
20 Dec 2023

https://www.businesswire.com/news/home/20230920030599/en

BUSINESSWIRE
20 Sep 2023

https://www.ema.europa.eu/en/documents/overview/kinpeygo-epar-medicine-overview_en.pdf

EMA
21 Aug 2023

https://www.prnewswire.com/news-releases/fda-grants-priority-review-for-full-approval-of-tarpeyo-for-the-treatment-of-iga-nephropathy-301904398.html

PR NEWSWIRE
18 Aug 2023

https://www.prnewswire.com/news-releases/viatris-announces-launch-of-breyna-budesonide-and-formoterol-fumarate-dihydrate-inhalation-aerosol-the-first-fda-approved-generic-version-of-symbicort-for-people-with-asthma-and-chronic-obstructive-pulmonary-disease-in-partn-301888925.html

PR NEWSWIRE
01 Aug 2023

https://www.prnewswire.com/news-releases/everest-medicines-announces-completion-of-patient-enrollment-in-nefecon-china-open-label-extension-study-301889813.html

PR NEWSWIRE
31 Jul 2023

https://www.ema.europa.eu/en/documents/overview/kinpeygo-epar-medicine-overview_en.pdf

EMA
17 Jul 2023

https://www.prnewswire.com/news-releases/calliditas-therapeutics-submits-supplemental-new-drug-application-to-us-food-and-drug-administration-for-full-approval-of-tarpeyo-301856435.html

PR NEWSWIRE
21 Jun 2023

https://www.prnewswire.com/news-releases/everest-medicines-announces-partner-calliditas-therapeutics-reports-positive-topline-results-from-phase-3-nefigard-trial-evaluating-nefecon-in-iga-nephropathy-301770194.html

PR NEWSWIRE
13 Mar 2023

https://www.fiercepharma.com/pharma/astrazenecas-first-class-rescue-inhaler-airsupra-wins-fda-nod-only-adult-use

Eric Sagonowsky FIERCE PHARMA
12 Jan 2023

https://endpts.com/astrazeneca-nabs-6-more-months-for-symbicort-patent-in-latest-court-ruling/

Beth Snyder Bulik ENDPTS
17 Dec 2022

https://www.ema.europa.eu/en/documents/overview/kinpeygo-epar-medicine-overview_en.pdf

EMA
23 Nov 2022

https://www.prnewswire.com/news-releases/calliditas-partner-everest-medicines-new-drug-application-for-nefecon-is-accepted-by-the-china-nmpa-301678047.html

PRNEWSWIRE
16 Nov 2022

https://www.fiercebiotech.com/biotech/yes-no-maybe-fda-panel-delivers-mixed-verdict-astrazenecas-asthma-rescue-medication

Nick Paul Taylor FIERCEBIOTECH
10 Nov 2022

https://www.prnewswire.com/news-releases/kidney-international-publishes-results-from-nefigard-phase-3-trial-evaluating-tarpeyo-budesonide-in-iga-nephropathy-301653694.html

PRNEWSWIRE
19 Oct 2022

https://www.calliditas.se/en/kidney-international-publishes-results-from-nefigard-phase-3-trial-evaluating-tarpeyo-budesonide-in-iga-nephropathy-4246/

PRESS RELEASE
19 Oct 2022

https://www.fiercebiotech.com/biotech/fda-nixes-eua-ambitions-eigers-covid-treatment-proposes-full-approval-pathway-instead

Max Bayer FIERCEBIOTECH
06 Oct 2022